# 10 — THE OTHER TRACK: how "de minimis" became *law* *The dossier traces de minimis as a chain of toxicologists citing each other (Frawley 1967 → NAS 1969 → Rulis 1987 → 21 CFR 170.39 (1995) → TTC). That is the **science/citation** lineage. It ran alongside a second, **judicial** lineage — the federal-courts doctrine that actually carries the name "de minimis" and that supplied the **legal authority** the 1995 rule needed. The two tracks converge in the 1995 Threshold of Regulation rule. This file reconstructs the legal track and ties it back to Frawley.* **Grading as elsewhere:** **[CONFIRMED-primary]** (primary read) · **[P-cite]** (locator confirmed, opinion body not yet read directly this session) · **[secondary]** · **[absence-of-evidence]**. *No invented locators.* **Update (2026-06-10):** *Monsanto*'s de minimis passage has now been pulled **verbatim** from the opinion (CourtListener opinion **7840898**, 613 F.2d at 956; reproduced in §2), independently corroborated by FDA's rendering in the 1995 Federal Register and by vLex (which also confirms the caption and disposition). **All four case holdings are now [CONFIRMED-primary].** The full opinions for all three cases are **archived locally in `sources/`** (`Monsanto-v-Kennedy_613F2d947…txt`, `PublicCitizen-v-Young_831F2d1108…html`, `Les-v-Reilly_968F2d985…txt`; indexed in `sources/_SOURCES_INDEX.md`) — no longer dependent on a live fetch. --- ## 0. Headline - **The science chain doesn't explain how the idea became enforceable law. The court chain does.** When Frawley proposed his exemption (1966–68) and FDA's Ramsey tried to operationalize it (1969–71), FDA **abandoned it as legally unworkable** (3 Jun 1971) — i.e., the agency believed it **lacked statutory authority** to wave trivial migrants past the "food additive" definition. **[secondary]** (Heckman; register D4). - **A court then granted that authority.** *Monsanto Co. v. Kennedy*, **613 F.2d 947 (D.C. Cir. 1979)** (Leventhal, J.) held the FDA Commissioner *may* decline to treat a substance as a "food additive," despite the literal statutory definition, where migration is **"so negligible as to present no public health or safety concerns"** — a **de minimis** judgment. **[CONFIRMED-primary]** (opinion verbatim, 613 F.2d at 956; corroborated by FDA, 60 FR at 36584). - **A direct institutional through-line to Frawley:** the **co-petitioner** beside Monsanto was **the Society of the Plastics Industry** — *the same trade group that ran Frawley's 1967–68 de minimis campaign* (chaired by Hercules's Robert M. Miller; see `08_VINYL_CHLORIDE_CAMPAIGN.md`). SPI lost the administrative fight for Frawley's number in 1968 and won the **legal principle** in 1979. **[CONFIRMED-primary]** (caption) + **[CONFIRMED-primary]** (the SPI/Frawley campaign, `07`/`08`). - **The courts also fixed de minimis's ceiling — exactly where Frawley had drawn his own carve-out.** *Public Citizen v. Young*, **831 F.2d 1108 (D.C. Cir. 1987)** (Williams, J.), and *Les v. Reilly*, **968 F.2d 985 (9th Cir. 1992)** (Schroeder, J.), held the **Delaney anti-cancer clauses admit no de minimis exception** — no trivial-risk escape for a carcinogen. **[CONFIRMED-primary]** (verbatim below). - **…yet a calculated trivial-risk threshold was built *inside* the carcinogen statute anyway (§3.5).** The **1962 DES Proviso** let a carcinogenic animal drug through on "no residue"; when detection beat "zero," FDA's **Peter Barton Hutt** redefined "no residue" as the dose giving a lifetime cancer risk **below one in a million (10⁻⁶)** on a no-threshold model (final "Sensitivity of the Method" rule, **52 FR 49572**, 1987). It is Frawley's round-number move performed on the no-threshold class — and **the 1995 rule's 0.5 ppb is the same 10⁻⁶ calculation** (§4). **[CONFIRMED-primary]** (Rodricks 2019, register **H1**; 60 FR local text). - **The 1995 rule is the convergence.** **21 CFR 170.39** (60 FR 36582, 17 Jul 1995) grounds itself **expressly in *Monsanto*'s de minimis authority**, names the doctrine in Latin (**"de minimis non curat lex — the law does not concern itself with trifles,"** the very maxim Frawley quoted in 1967–68), and **conditions the exemption on the substance "not having been shown to be" a carcinogen** — citing *Public Citizen v. Young*. The law thereby adopted **Frawley's own structure**: a presumptive safe-because-trivial level for "all other" chemicals, with carcinogens (and pesticides/heavy metals) carved out. **[CONFIRMED-primary]** (local FR text). > **Why this was missed:** the existing investigation read the 1995 FR for its *number* (0.5 ppb) and its > *citation silence* on Frawley (correct — the rule cites Rulis, not Frawley). It did **not** mine the same > document's **legal reasoning**, which names *Monsanto* and *Public Citizen v. Young* and rests the entire > rule on the judicial de minimis doctrine. The primary was already in `sources/`; only the doctrine was > unread. --- ## 1. Pre-history — FDA thought it *lacked* the power (1969–71) Frawley's proposal needed someone with authority to declare a class of migrants exempt. Inside FDA, **Lessel L. Ramsey** (Bureau of Science — and the FDA officer SPI had been working since Dec 1966; `08`) drafted the **"Ramsey Proposal"**: exempt indirect additives migrating at **≤50 ppb**. At a **3 June 1971** meeting FDA concluded it could **not proceed** — the concept was judged **"scientifically sound" but legally unworkable**. **[secondary]** (Heckman / PackagingLaw; register **D4**; master dossier §2.2). *This is the linchpin the legal track resolves.* "Legally unworkable" means FDA in 1971 did not believe the Food Additives Amendment let it exempt a substance that literally met the "food additive" definition. That belief is exactly what the D.C. Circuit overturned eight years later. --- ## 2. *Monsanto Co. v. Kennedy*, 613 F.2d 947 (D.C. Cir. 1979) — the doctrine is born | Field | Value | |---|---| | **Caption** | **Monsanto Company, and The Society of the Plastics Industry, Inc., Petitioners v. Donald Kennedy, Commissioner of Food and Drugs** | | **Court / panel** | D.C. Circuit; **Bazelon** (Sr.), **Leventhal** (author), **Robinson** | | **Argued / decided** | argued **15 Mar 1979**; decided **6 Nov 1979** | | **Locator** | 613 F.2d 947, 198 U.S.App.D.C. 214 | **Facts.** Monsanto's **acrylonitrile copolymer** beverage bottles (the "Cycle-Safe" container) shed trace **acrylonitrile monomer** into the beverage. The Commissioner ruled the copolymer a "food additive" whose safety was not demonstrated, and barred it. **[CONFIRMED-primary]** (FDA's recitation, 60 FR at 36584; secondary case summaries). *Note the chemistry: this is precisely Frawley's domain — monomer migration from a food-contact plastic, the "indirect additive" problem.* **Holding — the de minimis authority.** The court held the Commissioner **need not** treat every literal migrant as a regulated food additive. As FDA itself renders the holding, pin-cited to **613 F.2d at 956**: > "…the Commissioner of Food and Drugs … may determine that the level of migration into food of a > particular substance is so negligible as to present no public health or safety concerns and, in such > cases, may decline to define the substance as a food additive even though it comes within the strictly > literal terms of the statutory definition of a food additive." **[CONFIRMED-primary]** (60 FR at 36584, > quoting/rendering 613 F.2d at 956) The opinion's **own words** (Leventhal, J., **613 F.2d at 956**; pulled from CourtListener opinion 7840898, cross-confirmed by the 1995 FR rendering and vLex) — **[CONFIRMED-primary]**: > "There is latitude inherent in the statutory scheme to avoid literal application of the statutory > definition of 'food additive' in those *de minimis* situations that, in the informed judgment of the > Commissioner, clearly present no public health or safety concerns." > > "Thus, the Commissioner may determine based on the evidence before him that the level of migration into > food of a particular chemical is so negligible as to present no public health or safety concerns, even to > assure a wide margin of safety." > > "However, if the Commissioner declines to define a substance as a 'food additive,' though it comes within > the strictly literal terms of the statutory definition, he must state the reasons for exercising this > limited exemption authority." The Commissioner therefore also retains discretion **not** to exercise the exemption; FDA's paraphrase in the 1995 rule tracks the opinion exactly (60 FR at 36584). **Disposition (verbatim).** *"The decision of the Commissioner is affirmed in part, and in part is remanded to provide the opportunity for reconsideration"* — i.e. remanded to let the Commissioner exercise (and explain) the de minimis judgment on the acrylonitrile record. **[CONFIRMED-primary]** (opinion; vLex). **Doctrinal root (optional, for completeness).** *Monsanto* is the FDA-specific application of the general administrative **de minimis doctrine** the D.C. Circuit articulated the same era in **Alabama Power Co. v. Costle, 636 F.2d 323 (D.C. Cir. 1979)**. **[P-cite]** (not pulled; flagged in `05` for a clean read). --- ## 3. The ceiling — de minimis stops at the carcinogen line (1987, 1992) The doctrine has a hard limit: it cannot be used to read a trivial-risk exception **into the Delaney anti-cancer clauses**. Two opinions fix that limit — *at exactly the boundary Frawley himself drew* (he excluded carcinogens, pesticides, and heavy metals from his 0.1 ppm). ### 3.1 *Public Citizen v. Young*, 831 F.2d 1108 (D.C. Cir. 1987) - **Author / date:** **Stephen F. Williams, J.**; decided **23 Oct 1987**. *(Correction to a common misattribution to Bork, who sat on the court then but did not write it.)* **[CONFIRMED-primary]**. - **Facts:** FDA listed cosmetic color additives **Orange No. 17** and **Red No. 19** despite animal carcinogenicity, on quantitative-risk grounds — lifetime cancer risk **"one in 19 billion at worst"** (Orange No. 17) and **"one in nine million at worst"** (Red No. 19). **[CONFIRMED-primary]**. - **Holding — no de minimis under the color-additive Delaney Clause:** > "The natural — almost inescapable — reading of this language is that if the Secretary finds the additive > to 'induce' cancer in animals, he must deny listing." > "The language itself is rigid; the context — an alternative design admitting administrative discretion > for all risks other than carcinogens — tends to confirm that rigidity." > "We conclude, with some reluctance, that the Clause lacks such an exception." **[CONFIRMED-primary]** (law.resource.org reporter text). - **Disposition:** the Orange No. 17 / Red No. 19 listings **vacated**. - **Relevance:** the dyes here are the same *class* as Frawley's tabulated colorants (Citrus Red No. 2 and the azo dyes; `09`). Where his number met an explicit anti-cancer statute, the courts said the trivial-risk logic does not reach. ### 3.2 *Les v. Reilly*, 968 F.2d 985 (9th Cir. 1992) - **Author / panel / date:** **Schroeder, J.** (with **Chambers**, **Beezer**); decided **8 Jul 1992**. **[CONFIRMED-primary]**. - **Facts:** EPA let four carcinogenic pesticides — **benomyl, mancozeb, phosmet, trifluralin** — remain as food additives (residues concentrating in processed food) on a **de minimis / negligible-risk** theory, leaning on the NAS report ***Regulating Pesticides in Food: The Delaney Paradox* (1987)**. **[CONFIRMED-primary]**. - **Holding:** the FFDCA §409 Delaney Clause is **"clear and mandatory"** and admits **no de minimis exception**; EPA lacked authority to create one. **[CONFIRMED-primary]** (CourtListener text; the longer holding sentences read as lightly paraphrased in fetch — treat the short phrase as verbatim, the rest as faithful sense). - **Disposition:** EPA order **set aside**. - **Relevance:** the pesticide branch — Frawley's other explicit carve-out — reaches the same wall. (*The political sequel, the **Food Quality Protection Act of 1996**, repealed Delaney for pesticides and substituted a risk-based "reasonable certainty of no harm" — i.e. it legislated the de minimis the court forbade. Reserved as context; see `05`.)* --- ## 3.5 The carcinogen-side de minimis — 10⁻⁶ grown *inside* the Delaney statute (added 2026-06-11) §3 is only half the carcinogen story. The courts refused to **read** a trivial-risk exception into Delaney — but a *calculated* trivial-risk threshold was built into the carcinogen statute **from the inside**, by Congress and then by FDA's own math, years before *Public Citizen* (1987) and *Les* (1992). That threshold is the **10⁻⁶ "one in a million" lifetime cancer risk** — the carcinogen-side twin of Frawley's 0.1 ppm, and the number the 1995 rule's 0.5 ppb was engineered to stay under (§4). **The DES Proviso (1962).** Congress amended the Delaney Clause so a carcinogenic **animal drug** could be approved if **"no residue"** of it is found in edible tissue by an approved method (the FFDCA "Sensitivity of the Method" proviso, 21 U.S.C. §348(c)(3)(A)). **[CONFIRMED-primary]** that the proviso exists and what it did (Rodricks 2019, firsthand — register **H1**). **The statutory "no residue" text is now held locally too** — "no residue of the additive will be found by methods of examination prescribed or approved by the Secretary" — in the EPA *Legal Compilation* (register **D13**), alongside the 1958 Food Additives Amendment, the Delaney clause, and the DES/stilbestrol material. *(The SOM rule that puts the 10⁻⁶ number on the proviso — **52 FR 49572**, 1987 — is **now held and read**, register **H25**; quoted below.)* **"No residue" redefined as a calculated 10⁻⁶ dose.** When analytical chemistry outran "zero" in the 1970s, FDA — through General Counsel **Peter Barton Hutt** — redefined "no residue" not as undetectable but as a **dose corresponding to a lifetime cancer risk below a chosen round number**, estimated on a *linear, no-threshold model*. The biostatistical antecedent was **Mantel & Bryan's (1961) "virtually safe dose,"** which they pegged at a lifetime risk of **1 in 100 million (10⁻⁸)** — and which they themselves called **arbitrary**: their paper (now held, register **H11**, **[CONFIRMED-primary]**) states "absolute safety can never be unquestionably demonstrated," so one must instead "assume that a risk of 1/100 million is so low as to constitute 'virtual safety,'" adding that "**other arbitrary definitions of 'virtual safety' may be employed as conditions require**" (27 JNCI at 457). Hutt, "after extensive discussions," moved the target two orders of magnitude up, to **less than 1 in 1 million (10⁻⁶)**. Rodricks, who was in the room, records it verbatim — **[CONFIRMED-primary]** (register **H1**; `sources/Rodricks2019-Crump2018_10-6-origin_excerpt.md`): > "Mantel's risk target was 1 in 100 million, and the calculated doses corresponding to that excess lifetime > risk he labeled 'virtually safe.'" … "Hutt proposed that 'safe doses' for carcinogens such as DES could be > defined as those associated with lifetime risk levels of **less than 1 in 1 million**, when these risks were > estimated using a linear, no-threshold model." **The contemporaneous rulemaking record now confirms and dates that move — the number *moved* in the open.** The three earlier *Federal Register* stages are now held and read (**register H32, [CONFIRMED-primary]**; `sources/SOM-DES_1973-1979_10-8-to-10-6_origin_excerpt.md`): - **1973 proposal (38 FR 19226, 19 Jul 1973):** adopts Mantel-Bryan by name and sets the acceptable individual risk at **1/100,000,000 (10⁻⁸ — Mantel's number)**, conceding in FDA's own voice that "**absolute safety can never be conclusively demonstrated**" and that "the level defined by the Mantel-Bryan procedure is **an arbitrary but conservative level**." *(The 1973 derivation of the assay-sensitivity target is itself a stack of round-number stipulations — an assumed 10⁻⁸ "acceptable" risk, times a "very conservatively estimated" **0.10** probability of continuous dietary exposure (itself bounced off an assumed 10% disease incidence) — i.e., the arithmetic is sound but every input is stipulated; the "0.10 intermittent-exposure factor" nets out to a 10× relaxation of the required detection limit, dressed as conservatism.)* - **1977 final rule (42 FR 10412, 22 Feb 1977):** **moves the number up two orders of magnitude** — "Consequently, the final regulations establish **the maximum risk to be used in the Mantel-Bryan calculation as 1 in 1 million**… such a risk level can properly be considered **of insignificant public health concern**." - **1979 reproposal (44 FR 17070, 20 Mar 1979) §"8. Level of risk":** narrates and defends the change — the 1973 "1 in 100 million level of risk was **unduly limiting without substantial compensation in terms of public health**," so the criterion became "(1) **not significantly increase the human cancer risk** and (2)… **be as high as possible in order to permit the use of carcinogenic animal drugs**." The pick was between round numbers: "**It is difficult to choose between 1 in 1 million and 1 in 10,000 but the agency chose the more conservative number**" (suggestions had ranged "from 1 in 20,000 per lifetime to 1 in 100 million"). FDA frames 10⁻⁶ as the successor to the Lehman-Fitzhugh "**absolute safety factor**" method — the two round-number devices named in one paragraph. So Rodricks's "Hutt, after extensive discussions" (Hutt was GC through 1975) is corroborated and **dated**: the formal adoption is the Feb 1977 notice, the rationale the 1979 reproposal. Proposed in the early 1970s and settled by ~1979, the **"Sensitivity of the Method" final rule** issued at **52 FR 49572–49590 (31 Dec 1987)** — **now held and read in full, [CONFIRMED-primary], register H25** (`sources/FDA_SOM-rule_52FR49572_1987_no-residue-10-6_excerpt.md`). The rule states the number plainly: the permitted residue is "the concentration of residue of a carcinogenic compound that presents an insignificant risk… That concentration corresponds to **a maximum lifetime risk of cancer to the test animal on the order of 1 in 1 million**" (52 FR 49572). Three things the verbatim text nails down, that the secondary sources only implied: 1. **FDA does *not* call this de minimis.** It reaches 10⁻⁶ through "an **operational definition of 'no residue'**," and says so expressly: "This legal theory… **differs from the application to the Delaney Clause of the *de minimis* doctrine**, i.e., that the law does not concern itself with trifling matters" (52 FR 49573). So the carcinogen-side 10⁻⁶ rides into Delaney on **two** distinct vehicles — this "operational no residue" (animal-drug side) and the de minimis doctrine (color-additive side, struck in §3.1) — a belt-and- suspenders hedge against exactly the wall *Public Citizen* and *Les* delivered to the de minimis route. 2. **10⁻⁶ is an adopted consensus, not a derivation.** FDA records "a **clear consensus that risks on the order of 1 in 1 million were insignificant**, though the same degree of consensus did not obtain for potentially higher levels," while commenters urged that "**higher levels (e.g., 1 in 100,000 or 1 in 10,000) might also present insignificant risks**," and that the true risk lies "**some place between 1 in 1 million and a much lower indeterminable level**" (52 FR 49575–76). 3. **The number is built to thread a needle.** FDA's two criteria for the permitted level: "(1) It must not significantly increase the human cancer risk and (2) **it must be high enough to permit the use of carcinogenic animal drugs, food** [and color additives]" (52 FR 49576) — low enough to call "safe," high enough to keep the product legal. The companion "**constituents/impurities**" device (impurities "**not subject to the Delaney Clause**," 47 FR 14464) is named in the same preamble. This is the birth of **quantitative cancer-risk assessment** in U.S. law — and, on its own admission, the birth of a chosen round number. **Why it belongs in this file.** It is Frawley's exact move — *a round number standing in for a threshold the science denies* — performed on the one class of chemicals that has no threshold (genotoxic carcinogens; the single-cell realization, Crump 2018, register **H2**), and performed **through** the absolute statute. There is no contradiction with §3: the courts barred *judicially* reading a de minimis exception into a Delaney clause that lacks one; the DES Proviso is a *narrow statutory* off-ramp Congress itself wrote, which FDA then operationalized as a 10⁻⁶ calculation. The lesson is the dossier's throughline, not a paradox: the no-threshold carcinogen got a round-number threshold anyway — by statute-plus-agency-math here, by the food-contact rule in 1995. (The number's authors do not defend it as science: surveyed by Kelly, "The Myth of 10⁻⁶…" (1991, register **H12**, read firsthand), the officials who use it **could not document its origin** — "no scientific or regulatory basis… arbitrary." **[secondary]** for the survey's claims.) **The indirect root — the 10⁻⁶ branch grows off the factor-of-100 trunk.** Rodricks (register **H1**) records, firsthand, that the probabilistic 10⁻⁶ method was conceived at FDA to **replace the deterministic safety-factor approach "devised by … Arnold Lehman, and another FDA toxicologist, O. Garth Fitzhugh … published in the 1949 to 1955 period"** — i.e. the **100-fold margin of the first essay.** Crump (**H2**) confirms that before ~1960 even carcinogens were handled by that same NOAEL-safety-factor method; the 10⁻⁶ track split off only with the 1970s single-cell/no-threshold realization, whose premise Rodricks traces to "a community of experts working in … **chemical and radiation carcinogenesis**" (he names NCI's Arthur Upton, "a giant in the area of radiation risk," with Saffiotti and Schneiderman; the single-hit model itself is radiation target-theory, Lea 1946). **So the two round-number devices this dossier tracks — Frawley's 0.1 ppm (×100) and the carcinogen-side 10⁻⁶ — are two branches off one trunk: the Lehman–Fitzhugh safety factor.** And that trunk is **Frawley's own milieu**: Lehman ran the FDA Division of Pharmacology where Frawley worked; Fitzhugh (with Nelson) was Frawley's co-author. **[CONFIRMED-primary]** (Rodricks/Crump held). *The indirect root is now **primary-backed end to end**: Lehman & Fitzhugh 1954 (**H16**); the radiation-protection primaries — **Lea 1946** target theory (**H31**) and **NBS Handbook 59 / NCRP-17, 1954** (**H29**); and **Crump, Hoel, Langley & Peto 1976** (**H26**) — all held and read (only the ~5 unnamed "Friedman folder" papers remain a genuine bibliographic gap, `_WISHLIST.md` §🔵).* **The deepest root: the single hit (radiation), 1946–54.** Why does the carcinogen branch need a *number* at all, when the safety-factor trunk used a *threshold*? Because for genotoxic carcinogens the science says there is no threshold to find — and that conclusion was reached first in **radiation biology**, a generation earlier. **Lea (1946, register H31)** lays down the **target theory**: gene mutation is "due to a **single ionization**" of the gene molecule, so the dose-effect curve is exponential and **threshold-free** — one hit suffices. The radiation-protection committees drew the policy consequence in **NBS Handbook 59 / NCRP-17 (1954, register H29)**: "**there is no threshold dose for the production of gene mutations by radiation… strictly speaking there is no such thing as a tolerance dose**," so they retired "tolerance dose" and adopted a "**permissible dose**" defined by a risk "so small that it is **readily acceptable**." That is the conceptual headwater of "acceptable risk." **Crump et al. (1976, register H26)** then carried the single-hit logic into chemical carcinogenesis — linear-at-low-dose "under almost any model" — and named the lineage out loud: linear extrapolation should be publicly agreed "**as it was for radiation 20 years ago**" (1976 − 20 ≈ 1954). Mantel & Bryan (H11) had already borrowed Lea's target theory by name (their ref 12). So the carcinogen 10⁻⁶ is not merely a branch off the Lehman–Fitzhugh trunk; its no-threshold premise is **transplanted from radiation protection**, where "acceptable risk" replaced "safe dose" in 1954. Crump's own footnote 3 (H26) then concedes the cutoff is free: "**no compelling reason why the guarantee should be of an extra risk of 10⁻⁸ or less; if… 10⁻⁶, a few ppm might be permitted.**" The slope is physics; the round number is choice. **And the radiation root is a *military* root.** The committee that made the "acceptable risk" move was reorganized for the bomb: NBS Handbook 59's preface records that the radiation-protection committee "functioned effectively **until the advent of atomic energy**," whereupon (Dec 1946) it was enlarged into the National Committee on Radiation Protection — its roster listing **the U.S. Air Force (Maj. S. E. Lifton), the U.S. Army (Brig. Gen. J. P. Cooney), the U.S. Atomic Energy Commission (K. Z. Morgan and J. C. Bugher), and the U.S. Navy (Rear Adm. C. F. Behrens)** (NBS Handbook 59, ll. 125–128). So the device the carcinogen 10⁻⁶ runs on — "acceptable nonzero risk" in place of "safe dose" — was co-authored by the armed services and the weapons agency, to manage nuclear-weapons-program exposure. **One caveat the primaries force:** in 1954 they did **not** use 10⁻⁶ or any cancer *probability* — the limit was a **dose** (0.3 r/week) and "acceptable risk" was defined by *comparison* ("the risk essentially the same as is present in ordinary occupations," ll. 1372–73). The risk-*number* framing of radiation protection — and the radiation "de minimis / negligible risk" figure — arrives later (ICRP/NCRP, 1970s–80s) and is **a different number**: the NCRP **negligible individual risk level = 10⁻⁷ per year (1 mrem/yr); acceptable ≈ 10⁻⁵/yr** — *not* 10⁻⁶/lifetime (now held primary: Meinhold, ch. 11 of *De Minimis Risk*, 1987, register **H34**; analysis in `sources/Radiation-acceptable-risk_AEC-ICRP-NCRP_de-minimis_excerpt.md`, register **H33**). The two traditions were literally **bound in one 1987 volume** (chemical 10⁻⁶ in ch. 8, radiation 10⁻⁷/yr in ch. 11). The military DNA is on the **number** side of this story (radiation → acceptable risk), **not** the de minimis side (Frawley → SPI → the courts), which is civilian-commercial throughout. ## 4. The convergence — 21 CFR 170.39 (1995), grounded in the doctrine The Threshold of Regulation rule (**60 FR 36582**, 17 Jul 1995; local `sources/FDA_Threshold-of-Regulation_60FR36582_1995.txt`) is the codification of *Monsanto*'s de minimis authority for food-contact substances. From the preamble (**[CONFIRMED-primary]**, local text): - **It rests the rule on *Monsanto*.** "A Federal court has addressed the issue… In *Monsanto v. Kennedy*, 613 F.2d 947… the court stated that the Commissioner… may decline to define the substance as a food additive even though it comes within the strictly literal terms of the statutory definition" (60 FR at 36584). - **It names the doctrine — Frawley's own maxim.** Footnote 4: *"This doctrine is expressed in Latin as **de minimis non curat lex** (the law does not concern itself with trifles)."* (60 FR at 36585). Frawley used the identical maxim to the FDA's face in 1967–68 (`sections.md` §3; `_sourcepack`). - **It adopts Frawley's carcinogen carve-out, via *Public Citizen*.** Rejecting comments that *Monsanto* would let trivial carcinogen migrants escape Delaney: "a carcinogenic additive is deemed to be unsafe, no matter how low the exposure… or how low the risk (see *Public Citizen v. Young*, 831 F.2d 1108, 1122…)"; therefore the exemption is "conditioned on such substances **not having been shown to be carcinogens**" (60 FR at 36586). **[CONFIRMED-primary]**. - **The number.** Exempts food-contact substances at a dietary concentration **≤0.5 ppb** (≈1.5 µg/person/day). Cites **Rulis**, not Frawley. **[CONFIRMED-primary]** (already in `01`/`03`). - **Why 0.5 ppb — the number is itself a 10⁻⁶ calculation (the keystone, now extracted from the local text).** The rule does not pick 0.5 ppb as a round fraction of a toxic level; it reads it off a cancer-potency distribution. FDA "plotted the potencies [of **477 animal carcinogens**] as a probability distribution on a semilogarithmic scale and found that they formed a **bell-shaped distribution curve**," then "determined that most known carcinogens pose **less than one in a million** upper-bound lifetime risk if present in the daily diet at 0.5 ppb or less" (60 FR at 36583). So the food-contact threshold is the **same 10⁻⁶ device** as the DES/SOM rule (§3.5), built on the same linear-no-threshold logic. And the rule disclaims the first essay's number in the same breath: that 0.5 ppb "happens to be **200, rather than a 100, times lower**" than the pesticide toxic level "is merely coincidental and does not reflect the agency's reasoning" — while a comment it answers invokes "the **100-fold safety factor**." **[CONFIRMED-primary]** (local ll. 245–390). *This is the fact the prior reading of the FR missed: §11 of the essay said only "two hundred times under Frawley's figure" and never said why 0.5 ppb.* - **Only FDA may invoke it** — "only the Commissioner has the statutory authority to exempt a substance" (60 FR at 36586) — the discretionary half of *Monsanto*. --- ## 5. The through-line to Frawley (what the legal track adds to the story) 1. **Same trade group, two fights.** SPI championed Frawley's **administrative** de minimis number (1967–68, chaired by his employer's Robert M. Miller) and **lost** at FDA; SPI then co-litigated the **judicial** de minimis principle in *Monsanto* (1979) and **won**. The 1995 rule that embodies Frawley's *kind* of number was built on the authority SPI helped win. **[CONFIRMED-primary]** on both ends. 2. **"Legally unworkable" → legally authorized.** FDA abandoned the idea in 1971 for want of authority; the court supplied the authority in 1979; FDA codified it in 1995. The lag the essay tracks for the *science* (the number outliving its evidence) has a clean **legal** counterpart (the authority arriving after the agency had given up). 3. **The law ratified Frawley's exclusions.** His instinct — trivial level ⇒ presumed safe **except** for carcinogens/pesticides/heavy metals — is now the literal architecture of 21 CFR 170.39 (de minimis exemption, carcinogen-conditioned per *Public Citizen v. Young*). 4. **The maxim came full circle.** Frawley invoked *de minimis non curat lex* as rhetoric in 1967; the courts turned the maxim into doctrine; the 1995 rule recites the maxim in a footnote. The essay quotes Frawley using the tag (§3) — it can now show the tag becoming enforceable law (§11). --- ## 6. Open / next (for `05_OPEN_QUESTIONS`) - **Pull *Monsanto* 613 F.2d at 956 verbatim** from the bound reporter / Westlaw / Google Scholar to upgrade the de minimis sentence from **[P-cite]** to **[CONFIRMED-primary]** in its own words (FDA's rendering is already primary; this is for the essay's verbatim quote). Free hosts (Justia, OpenJurist, casetext, ELR) were CAPTCHA/410-blocked this session. - **Read *Alabama Power Co. v. Costle*, 636 F.2d 323 (D.C. Cir. 1979)** for the general administrative de minimis doctrine *Monsanto* applies (one paragraph of context). **[P-cite]**. - **Verbatim *Les v. Reilly* holding sentences** (CourtListener fetch lightly paraphrased) — confirm against 968 F.2d at 988–990. - ~~**Pull one DES "Sensitivity of the Method" Federal Register page** (esp. final **52 FR 49572**, 1987)~~ **✓ DONE 2026-06-13 — 52 FR 49572–49590 held and read in full (register H25); §3.5 flipped to [CONFIRMED-primary]** with the "1 in 1 million / operational no residue / differs from de minimis" text verbatim. ~~*Still wishlisted:* the **earlier** SOM pages (38 FR 19226 / 42 FR 10412 / 44 FR 17070)~~ **✓ DONE 2026-06-13 — all three held & read (register H32); §3.5 now carries the dated 10⁻⁸→10⁻⁶ trajectory** (1973 = Mantel's 10⁻⁸ "arbitrary"; 1977 final moves it to 10⁻⁶; 1979 §8 defends it). Mantel & Bryan 1961 (H11) and Kelly 1991 (H12) are also held. **The origin question is now closed on contemporaneous primary record.** - **Fold in Lowe (1989, register H27)** where §3.1 narrates *Public Citizen v. Young*: an FDA staffer's contemporaneous account corroborates the opinion ("with some reluctance," risks "trivial," "extraordinarily rigid… comprehensible policy choice") **and** openly names FDA's "common sense de minimis interpretation of the 'Delaney clause'" as agency policy — the institutional voice beside Frawley's. - **Reserved for later essays (per operator):** the **TTC / Cramer-class** machinery and the **genotoxic-TTC 0.15 µg/day** endpoint, and the **FQPA 1996** pesticide sequel — gestured as "not the end of the story," not developed here. --- ## 7. Locators | Item | Cite | Locator / source | Grade | |---|---|---|---| | *Monsanto Co. v. Kennedy* | 613 F.2d 947 (D.C. Cir. 1979), Leventhal, J. | 613 F.2d 947, **at 956**; 198 U.S.App.D.C. 214; CourtListener opinion **7840898** (`/opinion/7893633/`); corroborated at **60 FR 36584** (local) | **[CONFIRMED-primary]** (opinion verbatim + FR) | | SPI as co-petitioner | caption | reporter caption; OpenJurist title; vLex 886782951 | **[CONFIRMED-primary]** | | *Public Citizen v. Young* | 831 F.2d 1108 (D.C. Cir. 1987), Williams, J. | law.resource.org `F2/831/831.F2d.1108.86-5150.86-1548.html`; CourtListener `/opinion/496579/`; cert. denied 485 U.S. 1006 (1988) | **[CONFIRMED-primary]** | | *Les v. Reilly* | 968 F.2d 985 (9th Cir. 1992), Schroeder, J. | CourtListener `/opinion/586411/`; Justia `…/F2/968/985/98282/` | **[CONFIRMED-primary]** (core) | | NAS, *Regulating Pesticides in Food: The Delaney Paradox* | NRC 1987 | cited in *Les*; NAP catalog | **[P-cite]** | | Threshold of Regulation rule | 21 CFR 170.39; 60 FR 36582 (17 Jul 1995) | local `sources/FDA_Threshold-of-Regulation_60FR36582_1995.txt`; FR Doc 95-17435 | **[CONFIRMED-primary]** | | Ramsey Proposal "legally unworkable," 3 Jun 1971 | — | Heckman / PackagingLaw; register **D4** | **[secondary]** | | SPI/Frawley campaign (Miller chair; Keller & Heckman; Ramsey) | — | `07_TOXICDOCS_FINDINGS.md`, `08_VINYL_CHLORIDE_CAMPAIGN.md` | **[CONFIRMED-primary]** | | 10⁻⁶ origin: DES Proviso → Hutt's "1 in 1 million"; Mantel's 10⁻⁸ | Rodricks 2019; Crump 2018 | register **H1/H2**; `papers/lateral/`; excerpt `sources/Rodricks2019-Crump2018_10-6-origin_excerpt.md` | **[CONFIRMED-primary]** | | DES "Sensitivity of the Method" **final rule** | **52 FR 49572–49590** (31 Dec 1987); 21 CFR 500 Subpart E | **held & read in full** — `papers/lateral/FDA_SOM-rule_52FR49572_1987-12-31.pdf/.txt` (register **H25**); excerpt `sources/FDA_SOM-rule_52FR49572_1987_no-residue-10-6_excerpt.md` | **[CONFIRMED-primary]** | | earlier SOM rulemaking pages | **38 FR 19226** (1973, proposed) / **42 FR 10412** (1977, final) / **44 FR 17070** (1979, reproposed) | **held & read** (register **H32**) — `papers/lateral/SOM-DES_*.pdf/.txt` (archives.federalregister.gov slices); excerpt `sources/SOM-DES_1973-1979_10-8-to-10-6_origin_excerpt.md` | **[CONFIRMED-primary]** | | Lowe, "Risk Assessment and the Credibility of Federal Regulatory Policy: An FDA Perspective" | *Regul. Toxicol. Pharmacol.* 9:131–141 (1989); DOI 10.1016/0273-2300(89)90030-5 | held & read (register **H27**); `papers/lateral/lowe1989_rtp_risk-assessment-credibility-fda-perspective.pdf`; excerpt `sources/Lowe1989_FDA-de-minimis-Delaney-defense_excerpt.md` | **[CONFIRMED-primary]** | | 0.5 ppb = sub-10⁻⁶ off a 477-carcinogen bell curve; "200 vs 100… coincidental" | 60 FR 36582 at 36583 | local `sources/FDA_Threshold-of-Regulation_60FR36582_1995.txt` ll. 245–390 | **[CONFIRMED-primary]** | | Mantel "we just pulled it out of a hat"; officials' confessions | Kelly, "The Myth of 10⁻⁶…" (1991) | wishlisted (`papers/lateral/_WISHLIST.md`); attribute to Kelly | **[secondary]** | --- *Companion: `08_VINYL_CHLORIDE_CAMPAIGN.md` (the SPI campaign behind Frawley's number) · `01_MASTER_DOSSIER.md` §2.3 (propagation lineage) · `03_DOCUMENT_REGISTER.md` §D (de minimis record) · `04_TIMELINE.md`.*